Prolactinoma drug study: which strategy spares your blood sugar?
NCT ID NCT07045935
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 30 times
Summary
This study looks at how two different ways of using dopamine agonists (medicines that shrink prolactinomas) affect the body's ability to handle sugar. About 60 adults with prolactinoma will be randomly assigned to one of two treatment strategies. The main goal is to see which approach leads to better blood sugar control after a glucose drink test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLACTINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes
RECRUITINGBasel, 4031, Switzerland
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.